Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (491-500 of 527) with videos related to

Pageof 53
Sort By:
The Lancet. Oncology|December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Cognitive function depends upon <i>Satb2</i> gene dosage in cortical projection neuronsThomas S Finn, Jeremiah Tsyporin, Min Dai, et al.
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 TrialGontran Verset, Ivan Borbath, Mark Karwal, et al.
Oncotarget|August 18, 2015
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancerMeng-Lay Lin, Hetal Patel, Judit Remenyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2024
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline UpdateJohn D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1BAmy S Clark, Fangxin Hong, Richard S Finn, et al.
Advanced Materials Technologies|July 2, 2021
Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular CarcinomaNa Sun, Yi-Te Lee, Minhyung Kim, et al.
Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2017
Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma LesionsWon Young Tak, Shi-Ming Lin, Yijun Wang, et al.
Pageof 53

Showing results (491-500 of 527) with videos related to

Sort By:
Pageof 53
The Lancet. Oncology|December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Cognitive function depends upon <i>Satb2</i> gene dosage in cortical projection neuronsThomas S Finn, Jeremiah Tsyporin, Min Dai, et al.
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 TrialGontran Verset, Ivan Borbath, Mark Karwal, et al.
Oncotarget|August 18, 2015
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancerMeng-Lay Lin, Hetal Patel, Judit Remenyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2024
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline UpdateJohn D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1BAmy S Clark, Fangxin Hong, Richard S Finn, et al.
Advanced Materials Technologies|July 2, 2021
Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular CarcinomaNa Sun, Yi-Te Lee, Minhyung Kim, et al.
Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2017
Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma LesionsWon Young Tak, Shi-Ming Lin, Yijun Wang, et al.
Pageof 53